Editor's note: The person posting comments as "RJ Kirk" in Tuesday's BIO CEO Live Blog is not the chairman of Clinical Data.
NEW YORK (TheStreet) -- Small- and midsized biotech companies get a second day in the investor spotlight this week at the 13th annual BIO CEO & Investor Conference.
I'll be continuing my live-blogging from the BIO CEO conference today, presenting news updates and analysis live from the presentation rooms and breakout (Q&A) sessions.Biotech companies on my coverage list Tuesday include: Spherix (SPEX), SuperGen (SUPG), Clinical Data (CLDA), Cel-Sci (CVM), Aastrom Biosciences (ASTM), AVI BioPharma (AVII) and Neoprobe (NEOP). >>BIO CEO Conference Blog, Day 1 I'll also be reporting on presentations from StemCells (STEM), YM BioSciences (YMI), Ziopharm Oncology (ZIOP), Cell Therapeutics (CTIC), Icagen (ICGN) and Telik (TELK). The BIO CEO conference is sponsored by BIO, the biotech industry-lobbying group based in Washington, D.C., and typically invites small- and mid-cap biotech companies to present to an audience of institutional investors. Smaller biotech companies, in particular, lack extensive research coverage from investment banks, so this conference is a good way for these companies to get their stories in front of investors. This BIO CEO confab live blog will be similar to the real-time coverage I provided in January of the J.P. Morgan Healthcare Conference. Expect breaks in between my postings today because I'll be moving around the conference and waiting for companies to present throughout the day. I'll do my best to give you continuous coverage, but understand that I'm somewhat at the mercy of the AT&T network and my ability to type into my iPhone while weaving through crowds and listening to biotech executives speak. Your best bet is to check back into the live blog several times throughout the day. Like my previous live blogs, I want to keep today's coverage interactive, so feel free to ping me with comments and questions. I will publish and respond to as many of your comments and questions as I can. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV